Gomes Vivian Carla, Parodi F Ezequiel, Vasan Priya, Marston William A, Pascarella Luigi, McGinigle Katharine L, Wood Jacob C, Benrashid Ehsan, Farber Mark A
Division of Vascular Surgery, University of North Carolina, Chapel Hill, NC.
University of North Carolina School of Medicine, Chapel Hill, NC.
J Vasc Surg. 2025 May 28. doi: 10.1016/j.jvs.2025.05.039.
Previous literature demonstrated an association between preoperative proteinuria and mortality after endovascular repair of juxtarenal aortic aneurysms. The aim of this study is to evaluate the association of preoperative proteinuria on 1- and 5-year survival after fenestrated/branched endovascular repair (F/BEVAR) of thoracoabdominal aortic aneurysms (TAAAs), pararenal aortic aneurysms, and juxtarenal aortic aneurysms treated with patient-specific company-manufactured devices (CMDs) or off-the-shelf devices. The impact on kidney function after F/BEVAR was also analyzed.
A retrospective analysis was performed with prospectively collected data, including patients with complex anatomy aortic aneurysms who underwent F/BEVAR at a single institution from July 2012 to February 2024. All patients were treated with a company-manufactured device or off-the-shelf devices under a physician-sponsored investigational device exemption protocol. Patients were divided into two groups based on the preoperative urinalysis performed within 30 days before the index procedure: patients with trace or no proteinuria vs patients with proteinuria (1+, 30-100 mg/dL; 2+, 100-299 mg/dL; 3+, ≥300 mg/dL). Primary outcomes were 1-year and 5-year survival. Secondary outcomes were 30-day mortality, myocardial infarction, stroke/transient ischemic attack, acute kidney injury, and spinal cord ischemia. The follow-up protocol included imaging studies (chest, abdomen and pelvis computed tomography angiography, abdominal radiography, and renal-mesenteric duplex ultrasound examination) and laboratory analysis. Time-to-event analysis was performed with Kaplan-Meier plots compared through log-rank testing. Binary logistic regression model was designed to investigate predictors associated with 5-year survival after F/BEVAR.
A total of 454 patients underwent the F/BEVAR procedure; patients were 71.5% male and 15.4% Black, with a mean age of 72 ± 5.2 years. Sixty-seven patients (14.7%) had preoperative proteinuria of ≥30 mg/dL. Patients with and without preoperative proteinuria were similar in terms of demographics, aneurysm extension, and comorbidities, except for chronic kidney disease and cerebrovascular disease, which were more prevalent in patients with proteinuria (P < .001 and P = .011, respectively). There was no significant differences observed in 30-day mortality, acute kidney injury, spinal cord ischemia, stroke/transient ischemic attack, or myocardial infarction rates. The survival analysis demonstrated a significantly lower 1-year (77.9 ± 5.4% vs 89.4 ± 1.6%; P = .004) and 5-year survival (33.8 ± 8.8% vs 65.2 ± 3.0%; P = .002) among the patients with proteinuria when compared with individuals presenting trace or no proteinuria. Patients with preoperative proteinuria had a risk of death almost two times higher (odds ratio, 1.95; 95% confidence interval, 1.27-2.99; P = .002) and a risk of developing kidney failure requiring dialysis at 5 years more than eight times higher (odds ratio, 8.28; 95% confidence interval, 2.62-26.13; P ≤ .001). Proteinuria was a better predictor of mortality than a preoperative estimated glomerular filtration rate of <60 mL/min/1.73 m, which was not significantly associated with this adverse event (P = .060).
The presence of significant proteinuria preoperatively is associated with reduced 1- and 5-year survival after F/BEVAR procedure in patients undergoing repair for complex anatomy aortic aneurysms. Preoperative proteinuria can be used to aid in preoperative risk assessment of either survival or kidney function deterioration after F/BEVAR.
既往文献表明,术前蛋白尿与近肾主动脉瘤腔内修复术后死亡率之间存在关联。本研究旨在评估术前蛋白尿与采用定制公司生产器械(CMD)或现成器械治疗胸腹主动脉瘤(TAAA)、肾旁主动脉瘤和近肾主动脉瘤的开窗/分支腔内修复术(F/BEVAR)后1年和5年生存率之间的关联。同时分析F/BEVAR术后对肾功能的影响。
对前瞻性收集的数据进行回顾性分析,包括2012年7月至2024年2月在单一机构接受F/BEVAR治疗的复杂解剖结构主动脉瘤患者。所有患者均根据医生发起的研究器械豁免方案,使用公司生产的器械或现成器械进行治疗。根据手术前30天内进行的术前尿液分析,将患者分为两组:微量蛋白尿或无蛋白尿患者与蛋白尿患者(1+,30 - 100mg/dL;2+,100 - 299mg/dL;3+,≥300mg/dL)。主要结局为1年和5年生存率。次要结局为30天死亡率、心肌梗死、中风/短暂性脑缺血发作、急性肾损伤和脊髓缺血。随访方案包括影像学检查(胸部、腹部和骨盆计算机断层扫描血管造影、腹部X线摄影以及肾肠系膜双功超声检查)和实验室分析。采用Kaplan-Meier曲线进行生存分析,并通过对数秩检验进行比较。设计二元逻辑回归模型以研究与F/BEVAR术后5年生存率相关的预测因素。
共有454例患者接受了F/BEVAR手术;患者中男性占71.5%,黑人占15.4%,平均年龄为72±5.2岁。67例患者(14.7%)术前蛋白尿≥30mg/dL。术前有蛋白尿和无蛋白尿的患者在人口统计学、动脉瘤范围和合并症方面相似,但慢性肾病和脑血管疾病在有蛋白尿的患者中更为普遍(分别为P <.001和P =.011)。在30天死亡率、急性肾损伤、脊髓缺血、中风/短暂性脑缺血发作或心肌梗死发生率方面未观察到显著差异。生存分析表明,与微量蛋白尿或无蛋白尿的患者相比,有蛋白尿的患者1年生存率(77.9±5.4%对89.4±1.6%;P =.004)和5年生存率(33.8±8.8%对65.2±3.0%;P =.002)显著降低。术前有蛋白尿的患者死亡风险几乎高出两倍(比值比,1.95;95%置信区间,1.27 - 2.99;P =.002),5年发生需要透析的肾衰竭风险高出八倍多(比值比,8.28;95%置信区间,2.62 - 26.13;P≤.001)。与术前估计肾小球滤过率<60mL/min/1.73m²相比,蛋白尿是更好的死亡率预测指标,术前估计肾小球滤过率与这一不良事件无显著相关性(P =.060)。
术前存在显著蛋白尿与接受复杂解剖结构主动脉瘤修复的患者F/BEVAR术后1年和5年生存率降低相关。术前蛋白尿可用于辅助F/BEVAR术后生存或肾功能恶化的术前风险评估。